Clare Gentry, MD
Infectious Disease · Houston, TXNPI 1881635209
Payments from drug & device makers
Across 11 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$92
- Mylan Specialty L.p.$49
- OPKO Pharmaceuticals, LLC$31
- AstraZeneca$22
- Ferring Pharmaceuticals Inc.$21
- Aurinia Pharma U.S., Inc.$17
- plus $31 from 2 others
What the payments were for
- Food & beverage$265100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 1 | $92 |
| Mylan Specialty L.p. | 3 | $49 |
| OPKO Pharmaceuticals, LLC | 2 | $31 |
| AstraZeneca | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Amgen | 1 | $15 |
How this compares
$265 in reported general payments places this provider in the 40th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 47 | $185,682 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 37 | $178,088 |
| NuzyraOmadacycline Tosylate | 11 | $160,563 |
| Daptomycin | 18 | $65,906 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $49,672 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $47,775 |
| TivicayDolutegravir Sodium | 16 | $32,529 |
| Meropenem | 28 | $3,438 |
| Vancomycin Hcl | 17 | $2,312 |
| Cefepime Hcl | 12 | $1,767 |
| Levofloxacin | 27 | $1,730 |
| Doxycycline Hyclate | 55 | $1,139 |
| Azithromycin | 53 | $1,040 |
| Ethambutol Hcl | 21 | $826 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 30 | $729 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Houston
- Eleftherios MylonakisHouston$6.4M
- Roberto ArduinoHouston$2.1M
- Issam RaadHouston$2M
- Joseph GatheHouston$1.9M
- Kevin GrimesHouston$1.9M
- Jennifer WhitakerHouston$1.5M
- Karen VigilHouston$1.4M
- Roy ChemalyHouston$1.2M
- David HuangHouston$884K
- Luis OstroskyHouston$731K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.